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Background: Squamous cell carcinoma of tongue (SCCT) is expected to harbor unique clinico-pathological and
molecular genetic features since a significant proportion of patients are young and exhibit no association with
tobacco or alcohol.
Methods: We determined P53, epidermal growth factor receptor, microsatellite instability, human papilloma virus
infection and loss of heterozygosity status at several tumor suppressor loci in one hundred and twenty one oral
SCCT (SSCOT) samples and analyzed their association with clinico-pathological features and patient survival.
Results: Our results revealed a significantly higher incidence of p53 nuclear stabilization in early (as against late)
onset SCCOT. FHIT loss was significantly associated with p53 nuclear stabilization and the association was stronger
in patients with no history of tobacco use. Samples harboring mutation in p53 DNA binding domain or exhibiting
p53 nuclear stabilization, were significantly associated with poor survival.
Conclusion: Our study has therefore identified distinct features in SCCOT tumorigenesis with respect to age and
tobacco exposure and revealed possible prognostic utility of p53.
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Squamous cell carcinoma of tongue (SCCT) is believed
to be associated with late onset and tobacco use similar
to other Head and neck squamous cell carcinoma
(HNSCC) subtypes. An increased incidence in the young
[1] and in individuals with no history of smoking and
alcohol consumption [2] is reported for squamous cell
carcinoma of oral tongue (SCCOT). SCCOT has the
highest burden of young patients among all HNSCC
subtypes and a significant proportion of patients belong-
ing to this age group appear to include non-smokers [3].
In addition, young patients with SCCOT have frequent
loco-regional recurrence [4] and poor prognosis [3].
Despite advances in cancer therapy, SCCOT five year* Correspondence: bashyam@cdfd.org.in
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unless otherwise stated.survival rate has not improved in the last few decades
[5]. All these factors make SCCOT a unique HNSCC
subtype and yet molecular genetic studies designed specific-
ally for this important cancer have been rare; most studies
have been restricted to a single prognostic marker and/or a
small cohort of patients [6].
We have conducted a retrospective study involving
comprehensive molecular genetic and clinico-pathological
analyses of one hundred and twenty one SCCOT samples;
results revealed significant association of p53 nuclear
stabilization with age of onset, FHIT loss and survival.Methods
Patient samples
Previously untreated, surgically resected primary SCCOT
specimens were collected from three hospitals in Hydera-
bad, India following informed consent and approval from
respective hospital ethics committees (Institutional EthicsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cer Centre, Institutional Ethics Committee of Apollo Hos-
pitals and Ethics Committee of Omega Hospitals), as per
modified Helsinki declaration of 2008 (http://www.wma.
net/en/30publications/10policies/b3/). The study included a
total of 121 tumor/normal sample pairs (all oral tongue;
106 freshly resected and 15 archived); all samples were
from patients not associated with family history for any
cancer. Median age of patients was 50 years with a male to
female ratio of 2.0. Patients aged ≤45 years were considered
as ‘young’ where as those aged ≥46 were considered as
‘old’. Surgically resected fresh tumor and matched normal
tissues were collected in liquid nitrogen and preserved
at −70°C after collecting representative pieces in buff-
ered formalin for embedding in paraffin. 4 μM sections
from tumor and matched normal formalin fixed and
paraffin embedded (FFPE) blocks for each sample were
stained with hematoxylin and eosin (H&E) to evaluate
grade and absence of tumor infiltration, respectively.
Clinical data and information pertaining to use of to-
bacco, alcohol and family history were obtained via
personal interview in the form of questionnaire or
from hospital medical records. Majority of tumors
were well differentiated (86/121; 71.07%). Clinico-
pathological details of the patient samples are given in
Additional file 1: Table S1.
Immunohistochemistry (IHC)
IHC was performed as per standard protocols [7] on tis-
sues embedded into FFPE blocks mentioned above, as
per standard practice though we are aware that this slice
of tissue may not represent the whole tumor. 4 μM
tumor sections were deparafinized and rehydrated in
graded series of alcohol followed by heat induced epi-
tope retrieval in citrate buffer at pH 6.0 (for p53) or pro-
teinase K pretreatment (for epidermal growth factor
receptor (EGFR)) and subjected to peroxidase quenching
using 0.6% hydrogen peroxide in methanol. Sections
were incubated with 1 μg/ml anti-p53 (DO-1, EMD
Millipore Calbiochem, Darmstadt, Germany) or 0.15 μg/ml
anti-EGFR (Clone: 31G7, Zymed laboratories, Carlsbad,
CA, USA) antibodies separately for one hour followed by
incubation with HRP-conjugated anti-mouse secondary
antibody (Dako REAL Envision Detection System, Dako,
Glostrup, Denmark) for 30 minutes and subsequently with
DAB chromogen (Dako REAL Envision Detection System,
Dako, Glostrup, Denmark) for 3 and 7 minutes for p53 and
EGFR, respectively. Sections were counter stained with
hematoxylin. The slides were scored by two experienced
pathologists blinded for clinical and molecular data.
Samples exhibiting nuclear stain in more than 20% tumor
epithelium were considered as positive for p53. For EGFR,
staining intensity (negative, weak, moderate and strong)
and fractional epithelium positivity (≤25%, 25 ≤ 50%, 50 ≤75% and 75 ≤ 100%) were scored as 0–3. A summated score
greater than 3 was considered as positive.
DNA isolation
From FFPE blocks
8 μM FFPE tissue sections from tumor and matched
normal blocks were stained with hematoxylin after
deparaffinization. Tumor rich areas identified by the
pathologist were scraped off and DNA was isolated
using SDS-proteinase K lysis and subsequent phenol-
chloroform extraction followed by alcohol precipitation.
From frozen tissues
DNA was isolated from fresh resected tumor tissues
using the DNeasy Kit (Qiagen, Hamburg, Germany) as
per manufacturer’s protocol after confirming ≥70% neo-
plastic cellularity.
TP53 mutation and human papilloma virus (HPV) screening
Bidirectional sequencing of TP53 exons 5–8 was carried
out on a 3100 Genetic analyzer (ABI inc., Foster city,
CA, USA) after PCR amplification using FFPE tumor
DNA as template. Primer sequences are given in supple-
mentary Additional file 2: Table S2. Suspected in-dels
were confirmed using TA cloning vector (Invitrogen,
Carlsbad, CA, USA) as per standard procedure. PCR
based screening of HPV was carried out as per standard
protocol [7] with GP5+ and GP6+ primers using DNA
isolated from frozen tumor tissue as template. Primer se-
quences are given in supplementary Additional file 2:
Table S2.
Microsatellite instability (MSI) screening and loss of
heterozygosity (LOH) analysis
MSI analysis was performed for the 106 fresh samples
using the standard NCI panel of five microsatellites
(two mononucleotide repeats viz. BAT25 and BAT26
and three dinucleotide repeats viz. D2S123, D5S346
and D17S250) using FFPE DNA as template as de-
scribed earlier [8]. Primer sequences are listed in sup-
plementary Additional file 2: Table S2. Samples were
classified as MSI if two or more microsatellites exhib-
ited instability and as microsatellite stable (MSS) if one
or none exhibited instability.
LOH analysis was performed (only for fresh samples)
based on polymorphic microsatellites located close to
putative tongue cancer tumor suppressor genes includ-
ing tp53CA (TP53-17pl3.1), D3S1300 (FHIT-3p14.2) and
D9S1748 (CDKN2A-9p21). LOH status was also assessed
for all three dinucleotide microsatellites of the NCI
panel namely D2S123 (hMSH2-2p15-16), D5S346 (APC-
5q21) and D17S250 (BRCA1-17q11.2). Primer sequences
are listed in supplementary Additional file 2: Table S2.
Experimental procedure was identical to that of MSI
Table 1 Correlation of p53 nuclear stabilization with
patient age
Age n NS+ NS- p-value
Young (≤45 years) 46 36 10 0.0184
Old (≥46 years) 75 42 33
Total 121 78 43
n, Number of samples; NS+, Nuclear stabilization; NS-, Absence of
nuclear stabilization;
p value corresponds to Fisher’s exact test.
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earlier [7].
Statistical analysis
Association between clinico-pathological and molecular
variables was examined using Fisher’s exact test. Disease
specific survival time was calculated as the duration be-
tween tumor resection and death. For patients who were
lost to follow up or died of reasons other than SCCOT,
survival times were censored to the last date on which
patients were known to be alive. Kaplan-Meier method
was used to estimate survival probability. Log rank test
was used to estimate significant differences in survival
rates between different groups. Cox proportional hazards
model was used to assess the effect of covariates in
multivariate analysis.
Results
Among 121 samples analyzed, 78 (64.46%) exhibited p53
nuclear stabilization (Table 1 and Figure 1A and B).Figure 1 Immunohistochemistry based detection of p53 and EGFR in pr
(A) and negative staining (B) of p53 are shown. Panels C, D and E show re
respectively. Original magnification 100x.Surprisingly, we observed a significant difference (p =
0.0184) in p53 nuclear staining between young (36/46;
78.26%), and old (42/75; 56%) patients (Table 1). There
was no significant association however between p53
stabilization and tobacco use (data not shown). We next
screened mutations in exons 5–8 of TP53 that encode
the DNA binding domain and are known to harbor ma-
jority of mutations [9]. Mutations (listed in Additional
file 3: Table S3), were detected in fifteen of thirty five
tumor samples that exhibited p53 nuclear stabilization
and in three of twenty six that did not. We did not ob-
serve differences in frequency of mutation in young and
old patients stratified by p53 nuclear stabilization (5/16,
31.25% in young and 10/19, 52.63% in old among p53
positive tumors; and 0/5, 0% in young and 3/21, 14.28%
in older patients among p53 negative tumors). Propor-
tion of transitions, transversions and indels were similar
to previous reports for SCCT as per the International
Agency for Research on Cancer TP53 database (Additional
file 4: Figure S1) and were not significantly different be-
tween the two age groups (data not shown). We identified
a novel 33 bp deletion, c.616-648del33 (Additional file 5:
Figure S2), located in exon 5 in a p53 positive tumor sam-
ple obtained from a chronic tobacco chewer that is ex-
pected to result in loss of eleven amino acids (143–153).
The deleted amino acids include four (143–146) that form
part of β-sheet S3 which is important in stabilizing the
loop- β sheet- α helix motif, a key domain in formation of
p53 DNA binding surface [10]. Majority of p53 positive tu-
mors harboring mutation (12/15) exhibited p53 positivityimary SCCOT samples. Representative results of nuclear stabilization
presentative results for strong, moderate and weak EGFR staining,
Table 2 LOH frequency at different loci
Microsatellite D2S123/hMSH2 D5S345/APC D17S143/BRCA2 TP53CA/TP53 D3S1300/FHIT D9S1748/CDKN2A
Informative cases 94 95 90 98 91 89
Frequency of LOH* 2.12 (02) 6.31 (06) 6.67 (06) 11.22 (11) 26.37 (24) 28.09 (25)
LOH, loss of heterozygosity.
*In percentage; Number of samples exhibiting LOH is shown in parenthesis.
Table 4 Correlation of FHIT LOH with p53 stabilization
Adduri et al. BMC Clinical Pathology 2014, 14:37 Page 4 of 8
http://www.biomedcentral.com/1472-6890/14/37in greater than 50% tumor cells (Additional file 3: Table
S3). In contrast, frequency of mutation was significantly
lower (3/14; 21.42%) (Additional file 3: Table S3) in p53
positive tumors exhibiting stabilization in less than 50%
cells. In addition, of the three p53 negative tumors that har-
bored p53 mutation, two exhibited complete absence
of staining. Interestingly, missense/inframe mutations
were predominantly identified in tumors exhibiting
p53 stabilization whereas frameshift mutations result-
ing in protein truncation were identified exclusively in
p53 negative tumors (Additional file 3: Table S3).
A significant proportion of HNSCC has been found to
express EGFR at high levels [11] and the same was ob-
served in the current study as well (97/121; 80.17%)
(Additional file 6: Table S4) (Figure 1C-E). There was no
significant difference in EGFR staining in tumors from
young and old patients (data not shown). We also ana-
lyzed EGFR expression status in matched normal sam-
ples for 25 tumors; staining was weak to moderate and
was limited to the basal and suprabasal layers (non-kera-
tinized cells). In the corresponding tumors however,
strong staining was observed throughout the tumor
(data not shown). In addition, in normal epithelium,
staining was observed predominantly in cell membrane
whereas in tumor cells, cytoplasmic staining was also
observed (data not shown).
PCR based screening revealed low proportion of HPV
infection (14/106; 13.2%) (Additional file 6: Table S4)
and MSI 14/106 (13.2%) (Additional file 7: Figure S3A-
E) in our sample cohort. Dinucleotide microsatellites
exhibited frequent instability (40/318; 12.58%) compared
to mononucleotide microsatellites (13/212; 6.13%) (data not
shown). LOH was more frequently observed in CDKN2A
(28.09%) and FHIT (26.37%) than other loci tested (Table 2)
(Additional file 7: Figure S3F-G). Nineteen of fifty six sam-
ples (33.92%) positive for p53 staining in contrast to only
five of thirty five (14.29%) p53 negative samples, exhibitedTable 3 Correlation of p53 stabilization with FHIT LOH
FHIT
status
n p53 status p-value
NS+ NS-
FHIT LOH+ 24 19 05 0.0508
FHIT LOH- 67 37 30
FHIT LOH+, FHIT LOH present; FHIT LOH-, FHIT LOH absent; NS+, p53 Nuclear
stabilization; NS-, absence of p53 nuclear stabilization; n, Number of samples;
LOH, loss of heterozygosity.
p value corresponds to Fisher’s exact test.LOH at FHIT indicating FHIT loss could be a more fre-
quent event in tumors exhibiting p53 nuclear stabilization
(p = 0.0508) (Table 3). In addition, this association was
stronger (p = 0.0094) in patients with no history of tobacco
use (Table 4).
Survival data was collected for a total of seventy nine
patients; median survival was 30.5 months. Though we
did not detect correlation of disease specific survival
with pathological stage or grade, there is a significant
difference in survival rate between patients with p53
positive and negative tumors (p = 0.0003) (Figure 2A and
Table 5). As expected, patients with tumors harboring
p53 DNA binding domain mutation were significantly
associated with poor survival (p = 0.0117) (Figure 2B and
Table 5). FHIT loss also exhibited significant effect on
disease specific survival (p = 0.0302) (Figure 2C and
Table 5) but it was not an independent predictor of
worse prognosis, as determined by Cox proportional
hazard model.
Discussion
Abrogation of p53 tumor suppressor activity is a fre-
quent event in many cancers, including HNSCC [12].
The frequency of p53 nuclear stabilization identified in
SCCOT in the present cohort (64.46%) is in accordance
with previous reports from India [13] as well as from
the West [14]. Interestingly, frequency of p53 nuclear
stabilization was high in young patients (Table 1), sug-
gesting possible role of genetic factors. An earlier study
conducted on 724 HNSCC cases reported a similar dif-
ference of p53 stabilization between young and older pa-
tients [15]. Of interest, a study conducted on aging mice
showed a two-fold decline in p53 activity with advancing
age, when exposed to radiation [16]. It can perhaps be
postulated that age related decline in p53 transcriptionaland tobacco use
P53
status
n Tobacco users (50) Tobacco never users (23)
FHIT LOH+ FHIT LOH- FHIT LOH+ FHIT LOH-
NS+ 45 09 24 08 4
NS- 28 04 13 01 10
p value = 0.0094
FHIT LOH+, FHIT LOH present; FHIT LOH-, FHIT LOH absent; NS+, p53 nuclear
stabilization; NS-, absence of p53 nuclear stabilization; n, Number of samples;
LOH, loss of heterozygosity.







































Figure 2 Kaplan Meier curves of disease specific survival of SCCOT patients based on p53 nuclear stabilization (A), TP53 mutation (B)
and FHIT LOH status (C).
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in old patients perhaps by mimicking mutational inactiva-
tion. The distinct occurrence of TP53 mutation exclusively
in samples exhibiting strong or absent p53 immunostain
has been observed earlier in ovarian cancer [17]. However,
we cannot rule out the possibility of dilution of mutant al-
lele by the wild type allele in samples exhibiting p53 stain-
ing in less than 50% cells. Since p53 mutations were also
identified in samples not exhibiting nuclear stabilization,
using immunostaining alone to identify p53 status may notbe an ideal approach. Interestingly, we observed that young
patients with p53 nuclear stabilization also exhibited DNA
binding domain mutation similar to older SCCOT patients.
This is in contrast to a study conducted on SCCOT pa-
tients in USA where none of the young patients who exhib-
ited p53 nuclear stabilization harbored mutation [18,19].
There is no previous report of HPV screening performed
specifically on SCCOT from India, though few studies on
oral squamous cell carcinoma (OSCC) revealed a higher
frequency of HPV infection [20], probably due to inclusion
Table 5 Association of p53 nuclear stabilization and FHIT loss with disease specific survival of SCCOT patients
Total (n) Dead (n) % Dead Median survival (months) Hazard ratioa 95% CI Significanceb
Total 79 42 53.16
P53 nuclear stabilization
NS- 30 10 33.3 63 - - 0.0003
NS+ 49 32 65.31 26.5 3.35.1 1.8293-6.1350
P53 mutation
Mutation 18 12 66.67 22 0.0117
No mutation 43 22 51.16 38 0.4274 0.1811 to 1.0084
FHIT LOH
LOH 20 13 65 21 - - 0.0302
No LOH 53 27 50.94 38 0.4967 0.2265-1.0893
aHazard ratio was calculated to the first variable in a subgroup (indicated by empty cells).
bCorresponds to Log Rank test (Mantel-Cox).
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carcinoma is known to exhibit higher frequency of HPV in-
fection [21].
Previous studies undertaken on HNSCC showed sig-
nificant variation in MSI (ranging from 1- 65%) across
populations, though number of markers analyzed varied
significantly [22-24]. Our results suggest the presence of
a higher frequency of MSI in SCCOT compared to other
HNSCC subtypes, as also reported previously [22]. In
this study, dinucleotide microsatellites exhibited fre-
quent instability compared to mononucleotide microsa-
tellites perhaps suggesting the occurrence of a distinct
form of instability than the one observed in classical
mismatch repair (MMR) deficient tumors [25]. A signifi-
cant proportion (one-third) of tumors exhibited LOH at
D9S1748 (CDKN2A) consistent with earlier reports [26].
LOH frequency of D2S123 (hMSH2), D5S346 (APC) and
D17S250 (BRCA1) observed in our patient cohort ap-
peared to be lower than previous reports [24]. An earlier
report from India revealed marginally higher frequency
of LOH at TP53 locus in oral cancer [27], probably due
to influence of tumors other than SCCOT.
FHIT harbors one of the most common fragile sites in
the genome called FRA3B and is often associated with
chromosomal deletions in various cancer cell lines and
tumors [28]. P53 inactivation induced genomic instabil-
ity could be one cause for the association of p53 nuclear
stabilization with FHIT loss though a similar association
with CDKN2A LOH was not identified. FHIT loss can
be expected to be more susceptible to genomic instabil-
ity given its location within a chromosomal breakpoint
region [28]. Strong association of loss of FHIT and p53
inactivation in nonsmokers (Table 4) suggests that tu-
mors occurring in tobacco never users with and without
p53 inactivation could be distinct entities. Wild type p53
and FHIT are known to have similar roles in inducing
apoptosis and cell cycle arrest possibly through Bak andp21 respectively [29]. Therefore, inactivation of FHIT
and p53 may facilitate tumor cells to evade apoptosis
and escape G0/G1 arrest. A recent report suggests that
inactivation of both FHIT and p53 may have possible
synergistic effect resulting in deregulation of prolifera-
tion related genes in lung cancer cell lines and tumors
[30], particularly in squamous cell carcinoma subtype of
non-small cell lung cancer [31]. Ours is however the first
study to report such association in SCCOT (Table 3).
To our knowledge, this is the first report to identify
p53 inactivation as an independent prognostic marker
for poor survival in SCCOT, though it has been reported
in HNSCC [32] and OSCC [33]. Few studies have identi-
fied FHIT to be a predictor of poor survival in OSCC
[34] in HNSCC [35]. However, these studies did not
analyze the status of p53 aberrations in the tumors. The
association of FHIT loss with poor survival is probably a
result of association with p53 nuclear stabilization.
Conclusion
Though the study was conducted on a relatively smaller
size of samples, it is expected to help in selecting mo-
lecular markers for larger studies in the future with
more clinical significance. However, this is the most
comprehensive molecular genetic study undertaken on
Indian SCCOT patients and has identified frequent mu-
tational inactivation of p53 and its significant association
with loss of FHIT. More importantly, our results show
association of wild type p53 and good survival. Genetic
aberrations contributing to concomitant FHIT loss and
p53 stabilization in tumors need to be delineated. It
would be interesting to study tumorigenesis pathways
contributing to SCCOT in the absence of p53 and FHIT
inactivation. Given the unique clinico-pathological fea-
tures associated with SCCOT, this study is an important
step towards understanding of this important but hith-
erto poorly studied HNSCC subtype.
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